In this issue:
CDK4/6 inhibitor + ET in hormone receptor+, HER2-zero/low-positive metastatic breast cancer
Race-specific association of BMI with specific molecular breast cancer subtypes
Alzheimer’s disease after hormone-modulating therapy for breast cancer
Oestrogen receptor-targeted PET in oestrogen receptor+ breast cancer
Frontline abemaciclib + nonsteroidal aromatase inhibitor in hormone receptor+, HER2− breast cancer
Neoadjuvant dose-dense vs. 3-weekly anthracycline-cyclophosphamide in triple-negative breast cancer
ET ± 1 year of everolimus in high-risk, hormone receptor+, early breast cancer
Relationship of exercise and distant recurrence in primary breast cancer
Fertility preservation and assisted reproduction in breast cancer interrupting adjuvant ET
Anastrozole dose escalation for oestrogen suppression in postmenopausal early-stage breast cancer
Please login below to download this issue (PDF)